Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings
Year: 2026
Type: article
Abstract: The spread of respiratory viruses, such as influenza and SARS-CoV-2, has presented significant challenges over the last 30 years, with few effective therapeutic options available to this day. Bicyclic peptides represent a unique, modular modality in the antiviral armamentarium against future pandemics. This study utilizes tool molecules to provide a deeper evaluation of multivalent bicyclic (Bicycle) molecule efficacy in several preclinical SARS-CoV-2 challenge settings. We explore both pre-exposure prophylaxis and post-exposure therapeutic settings via subcutaneous and intranasal routes of administration. We contextualize this further in bespoke scenarios where the immune system is compromised, as well as viral transmission. Promisingly, in all studies, we observe efficacy, significantly reducing infectious viral burden at each study endpoint. These data further support the candidacy of Bicycle molecules as a differentiated antiviral therapeutic class in the context of pandemic preparedness. IMPORTANCE: The COVID-19 pandemic triggered a rapid wave of innovation, accelerating the delivery of new vaccine technology and antiviral treatments. In our first paper, we described the discovery and molecular optimization of Bicycle molecules as a novel drug class for the potential treatment of SARS-CoV-2. Here, we have performed deeper characterization of these tool molecules in established animal models to evaluate scenarios for deployment, simulating SARS-CoV-2 transmission, testing more convenient delivery routes, such as intranasal, as well as looking at immunocompromised animals. The Bicycle molecules demonstrated positive outcomes in each of these studies and suggest that Bicycle molecules, as convenient and effective antiviral treatments, could be an important addition to help future preparedness against new viral pandemics.
Source: Journal of Virology
DOI: 10.1128/jvi.01224-26
Authors: Maximilian A. J. Harman, Katherine U. Gaynor, Guido Papa, Simone Pellegrino, Gustavo Arruda Bezerra, Brian McGuinness, Phillip Jeffrey, Paul Beswick, Steven Stanway, Katerine Van Rietschoten, Liuhong Chen, Anna Albecka, Ieva Drulyte, Jo Herriott, Edyta Kijak, Eduardo Gallardo-Toledo, Lee Tatham, Parul Sharma, Eleanor Bentley, Jo Sharp, Adam Kirby, Leo C. James, Andrew Owen, James P. Stewart, Michael J. Skynner
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: Wellcome Trust, Innovate UK
OpenAlex ID: W4414834010
